

Listă lucrări

a. Articole publicate in reviste indexate/cotate ISI Thompson Reuters-

1: Negru S, Papadopoulou E, Apessos A, Stanculeanu DL, Ciuleanu E, Volovat C, Croitoru A, Kakolyris S, Aravantinos G, Ziras N, Athanasiadis E, Touroutoglou N, Pavlidis N, Kalofonos HP, Nasioulas G. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. *BMJ Open*. 2014 May 23;4(5):e004652. doi: 10.1136/bmjopen-2013-004652. PMID: 24859998; PMCID: PMC4039802.

2: Volovat SR, Volovat C, Negru SM, Danciu M, Scripcariu V. The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis. *J Chemother*. 2016 Jun;28(3):235-41. doi: 10.1179/1973947815Y.0000000042. PMID: 26018108.

3: Volovat SR, Ciuleanu TE, Koralewski P, Olson JEG, Croitoru A, Koynov K, Stabile S, Cerea G, Osada A, Bobe I, Volovat C. A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer. *Oncotarget*. 2020 Aug 18;11(33):3105-3117. doi: 10.18632/oncotarget.27684. PMID: 32913555; PMCID: PMC7443368.

4: Săftescu S, Negru Ș, Volovăț S, Popovici D, Chercota V, Stanca S, Feier H, Malita D, Dragomir R, Volovăț C. Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers. *Exp Ther Med*. 2021 Jun;21(6):605. doi: 10.3892/etm.2021.10037. Epub 2021 Apr 14. PMID: 33936262; PMCID: PMC8082661.

5: Volovăț SR, Negru S, Stolniceanu CR, Volovat C, Lungulescu C, Scripcariu D, Cobzeanu BM, Stefanescu C, Grigorescu C, Augustin I, Lupascu Ursulescu C, Volovat CC. Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review). *Exp Ther Med*. 2021 May;21(5):535. doi: 10.3892/etm.2021.9967. Epub 2021 Mar 23. PMID: 33815608; PMCID: PMC8014970.

6: Himiniuc LM, Toma BF, Popovici R, Grigore AM, Hamod A, Volovat C, Volovat S, Nica I, Vasincu D, Agop M, Tirnovanu M, Ochiuz L, Negura A, Grigore M. Update on the Use of Nanocarriers and Drug Delivery Systems and Future Directions in Cervical Cancer. *J Immunol Res*. 2022 May 4;2022:1636908. doi: 10.1155/2022/1636908. PMID: 35571568; PMCID: PMC9095399.

7: Volovat SR, Augustin I, Zob D, Boboc D, Amurariti F, Volovat C, Stefanescu C, Stolniceanu CR, Ciocoiu M, Dumitras EA, Danciu M, Apostol DGC, Drug V, Shurbaji SA, Coca LG, Leon F, Iftene A, Herghelegiu PC. Use of Personalized Biomarkers in

Metastatic Colorectal Cancer and the Impact of AI. *Cancers (Basel)*. 2022 Oct 3;14(19):4834. doi: 10.3390/cancers14194834. PMID: 36230757; PMCID: PMC9562853.

8: Volovat SR, Volovat C, Miron I, Kanbay M, Goldsmith D, Lungulescu C, Badarau SC, Covic A. Oncogenic mechanisms in renal insufficiency. *Clin Kidney J*. 2020 Oct 23;14(2):507-515. doi: 10.1093/ckj/sfaa122. PMID: 33623673; PMCID: PMC7886561.

9: Ianole V, Danciu M, Volovat C, Stefanescu C, Herghelegiu PC, Leon F, Iftene A, Cusmuluc CG, Toma B, Drug V, Ciobanu Apostol DG. Is High Expression of Claudin-7 in Advanced Colorectal Carcinoma Associated with a Poor Survival Rate? A Comparative Statistical and Artificial Intelligence Study. *Cancers (Basel)*. 2022 Jun 13;14(12):2915. doi: 10.3390/cancers14122915. PMID: 35740581; PMCID: PMC9221359.

10: Volovat SR, Volovat C, Hordila I, Hordila DA, Mirestean CC, Miron OT, Lungulescu C, Scripcariu DV, Stolniceanu CR, Konsoulova-Kirova AA, Grigorescu C, Stefanescu C, Volovat CC, Augustin I. MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review. *Front Oncol*. 2020 Nov 20;10:526850. doi: 10.3389/fonc.2020.526850. PMID: 33330019; PMCID: PMC7716774.

11: Tincu CEI, Popa M, Atanase LI, Popa O, Ochiuz L, Postolache P, Ghizdov V, Irimiciuc SA, Agop M, Volovat C, Volovat S. Multi-fractal modeling of curcumin release mechanism from polymeric nanomicelles. *Drug Deliv*. 2022 Dec;29(1):2883-2896. doi: 10.1080/10717544.2022.2118402. PMID: 36062523; PMCID: PMC9448400.

12: Stolniceanu CR, Moscalu M, Azoicai D, Tamba B, Volovat C, Grierosu I, Ionescu T, Jalloul W, Ghizdov V, Gherasim R, Volovat S, Wang F, Fu J, Moscalu R, Matovic M, Stefanescu C. Improved Personalised Neuroendocrine Tumours' Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification. *J Pers Med*. 2021 Oct 17;11(10):1042. doi: 10.3390/jpm11101042. PMID: 34683183; PMCID: PMC8539645.

13: Scripcariu V, Scripcariu DV, Filip B, Gavrilescu MM, Muşină AM, Volovăţ C. "Liquid Biopsy" - Is it a Feasible Option in Colorectal Cancer? *Chirurgia (Bucur)*. 2019 Mar-Apr;114(2):162-166. doi: 10.21614/chirurgia.114.2.162. PMID: 31060647.

14: Cobzeanu BM, Popescu E, Danciu M, Paşca AS, Palade OD, Vonica SP, Rădulescu LM, Ungureanu LB, Moscalu M, Cobzeanu ML, Gheorghe Moisii L, Cobzeanu MD, Volovăţ C, Costan VV. Correlations between HPV, p53 and p16 in malignancies involving the retromolar trigone-opharynx junction. *Rom J Morphol Embryol*. 2019;60(3):853-859. PMID: 31912096.

15: Volovat SR, Ursulescu CL, Moisii LG, Volovat C, Boboc D, Scripcariu D, Amurariti F, Stefanescu C, Stolniceanu CR, Agop M, Lungulescu C, Volovat CC. The

06 SEP 23 

Landscape of Nanovectors for Modulation in Cancer Immunotherapy. *Pharmaceutics*. 2022 Feb 11;14(2):397. doi: 10.3390/pharmaceutics14020397. PMID: 35214129; PMCID: PMC8875018.

16: Cobzeanu BM, Cobzeanu MD, Moscalu M, Palade OD, Rădulescu L, Negru D, Moisii LG, Cobzeanu LM, Ungureanu LB, Vonica P, Matei DV, Rusu DC, Volovăț C, Costan VV. Predictive Value of HPV, p53, and p16 in the Post-Treatment Evolution of Malignant Tumors of the Oropharynx and Retromolar Trigone-Oropharynx Junction. *Medicina (Kaunas)*. 2020 Oct 15;56(10):542. doi: 10.3390/medicina56100542. PMID: 33076537; PMCID: PMC7602815.

17: Novello S, Scagliotti GV, Sydorenko O, Vynnychenko I, Volovat C, Schneider CP, Blackhall F, McCoy S, Hei YJ, Spigel DR. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study. *J Thorac Oncol*. 2014 Aug;9(8):1154-61. doi: 10.1097/JTO.0000000000000227. PMID: 25157768.

18: Mireștean CC, Volovăț C, Iancu RI, Iancu DPT. Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease. *J Clin Med*. 2022 Jan 26;11(3):616. doi: 10.3390/jcm11030616. PMID: 35160069; PMCID: PMC8836903.

19: Volovat C, Gladkov OA, Bondarenko IM, Barash S, Buchner A, Bias P, Adar L, Avisar N. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy. *Clin Breast Cancer*. 2014 Apr;14(2):101-8. doi: 10.1016/j.clbc.2013.10.001. Epub 2013 Oct 25. PMID: 24485296.

20: Volovat C, Bondarenko IM, Gladkov OA, Elsässer R, Buchner A, Bias P, Müller U. Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. *Springerplus*. 2015 Jul 3;4:316. doi: 10.1186/s40064-015-1067-7. PMID: 26155455; PMCID: PMC4489970.

21: Ailincăi D, Agop M, Marinas IC, Zala A, Irimiciuc SA, Dobreci L, Petrescu TC, Volovat C. Theoretical model for the diclofenac release from PEGylated chitosan hydrogels. *Drug Deliv*. 2021 Dec;28(1):261-271. doi: 10.1080/10717544.2021.1876181. PMID: 33501878; PMCID: PMC7850333.

22: Volovat C, Bondarenko I, Gladkov O, Buchner A, Lammerich A, Müller U, Bias P. Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients. *Support Care Cancer*. 2016 Dec;24(12):4913-4920. doi: 10.1007/s00520-016-3347-3. Epub 2016 Aug 8. PMID: 27501966.

23: Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková

04 SEP 23 

H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. *Lancet Oncol*. 2013 May;14(6):490-9. doi: 10.1016/S1470-2045(13)70102-5. Epub 2013 Apr 15. PMID: 23594786.

24: Maison-Blanche P, Vermorken JB, Goksel T, Machiels JP, Agarwala S, Rottey S, Daugaard G, Volovat C, Scheulen M, Sengeløv L, Grecea D, Eniu A, Jäger E, Meiri E, Cascinu S, Strumberg D, Demir G, Clemens M, Pinotti G, Nardi M, Guthrie T, Boelle E, Magherini E. A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. *J Cardiovasc Pharmacol*. 2013 Jun;61(6):495-504. doi: 10.1097/FJC.0b013e31828b73ff. PMID: 23429593.

25: Mireștean CC, Stan MC, Schenker M, Volovăț C, Volovăț SR, Iancu DTP, Iancu RI, Bădulescu F. Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers-Early Experiences from Romania and Literature Review. *Diagnostics (Basel)*. 2023 Aug 8;13(16):2620. doi: 10.3390/diagnostics13162620. PMID: 37627878; PMCID: PMC10452972.

26: Himiniuc LM, Socolov R, Nica I, Agop M, Volovat C, Ochiuz L, Vasincu D, Rotundu AM, Rosu IA, Ghizdov V, Volovat SR. Theoretical and Experimental Aspects of Sodium Diclofenac Salt Release from Chitosan-Based Hydrogels and Possible Applications. *Gels*. 2023 May 17;9(5):422. doi: 10.3390/gels9050422. PMID: 37233013; PMCID: PMC10218168.

27: Volovat S, Apetrii M, Stefan A, Vlad C, Voroneanu L, Hogas M, Haisan A, Volovat C, Hogas S. Cisplatin and AKI: an ongoing battle with new perspectives-a narrative review. *Int Urol Nephrol*. 2023 May;55(5):1205-1209. doi: 10.1007/s11255-022-03418-8. Epub 2022 Dec 12. PMID: 36508071.

28: Hirja AR, Voroneanu L, Siriopol D, Nistor I, Hogas S, Apetrii M, Volovat C, Veisa G, Mititiuc IL, Florea L, Onofrescu M, Covic A. Evaluation of low-dose glucocorticoid regimen in association with cyclophosphamide in patients with glomerulonephritis. *Int Urol Nephrol*. 2019 Oct;51(10):1805-1813. doi: 10.1007/s11255-019-02249-4. Epub 2019 Aug 5. PMID: 31385176.

29: Kamphuisen PW, Lee AYY, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; CATCH Investigators. Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study. *J Thromb Haemost*. 2018 Jun;16(6):1069-1077. doi: 10.1111/jth.14007. Epub 2018 Apr 17. PMID: 29573330.

30: von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J; APHINITY Steering Committee and Investigators. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. *N Engl J Med*. 2017 Jul 13;377(2):122-131. doi: 10.1056/NEJMoa1703643.

04 SEP 23 

Epub 2017 Jun 5. Erratum in: N Engl J Med. 2017 Aug 17;377(7):702. Erratum in: N Engl J Med. 2018 Oct 18;379(16):1585. PMID: 28581356; PMCID: PMC5538020.

31: Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017 Jul 27;377(4):352-360. doi: 10.1056/NEJMoa1704174. Epub 2017 Jun 4. PMID: 28578607.

32: Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gaurer TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25. PMID: 26406148; PMCID: PMC5719487.

33: Armasu I, Volovăţ C, Drug VL, Crumpei I, Vasiliu I, Tofan M, Preda C, Serban IL, Vulpoi C. IMPLICATIONS OF GHRELIN AXIS IN BREAST CANCER--REVIEW. Rev Med Chir Soc Med Nat Iasi. 2015 Apr-Jun;119(2):302-9. PMID: 26204629.

34: Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1. PMID: 26045340.

35: Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Erratum in: Lancet Oncol. 2015 Jun;16(6):e262. PMID: 25877855.

36: Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA; INSPIRE investigators. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol: 2015

04 SEP 13 

Mar;16(3):328-37. doi: 10.1016/S1470-2045(15)70046-X. Epub 2015 Feb 18. PMID: 25701171.

37: Siriopol D, Hogas S, Veisa G, Mititiuc I, Volovat C, Apetrii M, Onofriescu M, Busila I, Oleniuc M, Covic A. Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis. *Int Urol Nephrol*. 2015 Mar;47(3):563-9. doi: 10.1007/s11255-014-0870-3. Epub 2014 Nov 26. PMID: 25425437.

38: Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9. PMID: 24331154.

39: Volovăţ C, Căruntu I, Costin C, Stefan A, Popa R, Volovăţ S, Siriopol D, Voroneanu L, Nistor I, Segall L, Covic A. Changes in the histological spectrum of glomerular diseases in the past 16 years in the North-Eastern region of Romania. *BMC Nephrol*. 2013 Jul 15;14:148. doi: 10.1186/1471-2369-14-148. PMID: 23855530; PMCID: PMC3716947.

40: Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. *N Engl J Med*. 2012 Dec 20;367(25):2407-18. doi: 10.1056/NEJMoa1205511. Epub 2012 Nov 3. PMID: 23121377; PMCID: PMC3760207.

41: Grecu F, Lapuşneanu A, Ferariu D, Volovăţ C, Pricop A, Scripcariu V, Diaconu C. Rezultate imediate in managementul chirurgical al tumorilor stromale gastrointestinale primare (gist)-- experienta clinicii a III-A chirurgicale [Early results of the surgical management of gastrointestinal stromal tumors (gist)--the experience of the 3rd surgical unit]. *Rev Med Chir Soc Med Nat Iasi*. 2012 Apr-Jun;116(2):506-14. Romanian. PMID: 23077945.

42: Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. *N Engl J Med*. 2012 Feb 16;366(7):601-9. doi: 10.1056/NEJMoa1108898. PMID: 22335737.

43: Volovăţ C, Volovăţ SR, Dogaru C, Vulpoi C. Evaluarea calităţii vieţii in cursul tratamentului adjuvant cu tamoxifen versus inhibitori de aromatază la paciente cu cancer mamar--un trial randomizat [Assessment of the quality of life of women with breast cancer in adjuvant treatment with tamoxifen or aromatase inhibitors--a randomized trial]. *Rev Med Chir Soc Med Nat Iasi*. 2011 Jan-

04 SEP 13 

Mar;115(1):53-7. Romanian. PMID: 21688560.

44: Ruf P, Kluge M, Jäger M, Burges A, Volovat C, Heiss MM, Hess J, Wimberger P, Brandt B, Lindhofer H. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. *Br J Clin Pharmacol*. 2010 Jun;69(6):617-25. doi: 10.1111/j.1365-2125.2010.03635.x. PMID: 20565453; PMCID: PMC2878603.

45: Cepoi V, Covic A, Volovăț C. Evaluări clinico-epidemiologice asupra incidenței unor boli cronice de rinichi, înregistrate în România și județul Iași, în perioada 2004-2008 [Clinical epidemiologic assessment of the incidence of chronic kidney diseases registered in Romania, Iași County, in the years of 2004-2008]. *Rev Med Chir Soc Med Nat Iasi*. 2009 Oct-Dec;113(4):1070-6. Romanian. PMID: 20191876.

46: Scripcariu V, Dajbog E, Lefter L, Danciu M, Ferariu D, Pricop A, Grigoraș M, Negru D, Volovăț C, Miron L, Drug V, Dragomir C. Features of pathological assessment in rectal cancer. *Rev Med Chir Soc Med Nat Iasi*. 2006 Jul-Sep;110(3):590-7. PMID: 17571550.

47: Gusbeth-Tatomir P, Ardeleanu S, Covic M, Căruntu ID, Volovăț C, Covic A. Epidemiologia bolii renale în România trecere în revistă a bazei de date regionale de biopsii renale din zona Moldovei (1995-2004) [Epidemiology of biopsy-proven renal disease in Romania: data from a regional registry in north-eastern Romania]. *Rev Med Chir Soc Med Nat Iasi*. 2006 Jul-Sep;110(3):540-7. Romanian. PMID: 17571542.

48: Covic A, Maftai ID, Mardare NG, Ioniță-Radu F, Totolici C, Tuță L, Golea O, Covic M, Volovăț C, Gusbeth-Tatomir P, Mircescu G. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. *J Nephrol*. 2006 Nov-Dec;19(6):794-801. PMID: 17173254.

49: Covic A, Schiller A, Volovat C, Gluhovschi G, Gusbeth-Tatomir P, Petrica L, Caruntu ID, Bozdog G, Velciov S, Trandafirescu V, Bob F, Gluhovschi C. Epidemiology of renal disease in Romania: a 10 year review of two regional renal biopsy databases. *Nephrol Dial Transplant*. 2006 Feb;21(2):419-24. doi: 10.1093/ndt/gfi207. Epub 2005 Oct 25. PMID: 16249204.

50: Covic A, Goldsmith DJ, Gusbeth-Tatomir P, Volovat C, Dimitriu AG, Cristogel F, Bizo A. Successful use of Molecular Absorbent Regenerating System (MARS) dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion. *Liver Int*. 2003;23 Suppl 3:21-7. doi: 10.1034/j.1478-3231.23.s.3.9.x. PMID: 12950957.

51: Covic A, Căruntu ID, Marian D, Volovăț C, Ghiciuc C, Costin C, Florea L, Cotuțiu C, Covic M. Prognosticul și tratamentul glomerulonefritei membranoase:

04 SEP 23 

studiu prospectiv pe 5 ani [Prognosis and treatment of membranous glomerulonephritis-a 5-year prospective study]. Rev Med Chir Soc Med Nat Iasi. 2000 Apr-Jun;104(2):63-74. Romanian. PMID: 12089993.

52: Covic AC, Goldsmith DJ, Florea L, Gusbeth P, Volovat C, Taranu T, Suditu N, Novac C, Covic M. Should CAPD be the first choice for dialysis in Romania? Audit of the Iasi 'C. I. Parhon' Dialysis Center: 1995-2000. Nephrol Dial Transplant. 2001 Oct;16(10):1996-2001. doi: 10.1093/ndt/16.10.1996. PMID: 11572887.

53: Târcoveanu E, Pleșa C, Chifan M, Daniil C, Niculescu D, Bârza M, Crumpei F, Florea N, Balan G, Volovăț C, Moisi L, Epure O. Tumora Klatskin [Klatskin's tumor]. Rev Med Chir Soc Med Nat Iasi. 1999 Jan-Jun;103(1-2):151-60. Romanian. PMID: 10756903.

54: Covic A, Iancu L, Apetrei C, Scripcaru D, Volovat C, Mititiuc I, Covic M. Hepatitis virus infection in haemodialysis patients from Moldavia. Nephrol Dial Transplant. 1999 Jan;14(1):40-5. doi: 10.1093/ndt/14.1.40. PMID: 10052474.

55: Covic A, Goldsmith DJ, Segall L, Stoicescu C, Lungu S, Volovat C, Covic M. Rifampicin-induced acute renal failure: a series of 60 patients. Nephrol Dial Transplant. 1998 Apr;13(4):924-9. doi: 10.1093/ndt/13.4.924. PMID: 9568851.

56: Iancu L, Covic M, Diculencu D, Apetrei C, Porumb S, Zugun F, Volovăț C, Duca M. Determinarea prevalenței anticorpilor față de virusul hepatitei C (anti-VHC) și a nivelelor serice ale proteinei C reactive la pacienți dializați cronic [The determination of the prevalence of antibodies to the hepatitis C virus (anti-HCV) and of the serum levels of C-reactive protein in chronic dialysis patients]. Rev Med Chir Soc Med Nat Iasi. 1995 Jan-Jun;99(1-2):129-33. Romanian. PMID: 9524669.

b. Lucrări publicate în abstract (volume de rezumate la conferințe naționale)

1. Miron L, Volovăț C. Hormonal treatment in oncology - a review. Volumul de rezumate la Simpozionul Național de Endocrinologie și al XII-lea Simpozion de endocrinologie clinică, Iași 3-5 mai 1995:371-372.

2. Miron L, Ciornea D, Volovăț C. Rolul chimioterapiei în tratamentul cancerului de col uterin: 27 cazuri. Volumul de rezumate la „Zilele medicale V. Dobrovici - Cancerul de col uterin” ed. IV, Iași 2-3 iunie 1995:188.

3. Volovăț C, Miron L. Corelații între aspecte psiho-sociale și durerea cronică în determinarea calității vieții la paciențele cu cancer de col uterin; studiu pe 26 cazuri. Volumul de rezumate la „Zilele medicale V. Dobrovici - Cancerul de col uterin” ed. IV, Iași 2-3 iunie 1995:189.

4. Volovăț C, Miron L. Studiul simptomatologiei subiective apărute în urma întreruperii intempestive a tratamentului cu Tamoxifen la paciențele cu cancer de sân. Volumul de

04 SEP 23 

rezumate la „Zilele medicale V. Dobrovici - Cancerul de col uterin” ed. IV, Iași 2-3 iunie 1995:243.

5.Miron L, Buiuc A, Volovăț C, Zugun-Eloae F. Categori diagnostice, prognostice și terapeutice la pacienții cu metastaze cu punct de plecare neprecizat. Volumul de rezumate la Conferința Națională de Oncologie - Poiana Brașov, 21-25 octombrie 1996; IV:2

6.C. Volovat , C. Novac, Experienta clinicii a II-a chirurgie cu privire la tratamentul cancerului de prostata local avansat- 19-22 sept 1996 – Conferinta nationala de urologie, Sinaia

7.Miron L, Volovăț C. Considerații asupra nefrotoxicității tratamentului cu Cisplatin la pacienții cu-cancere bronho-pulmonare. Volumul de rezumate la Congresul Național de Nefrologie Iași, 8-11 mai 1997;44:23.

8.Miron L, Volovăț C, Pagu L, Toma C. Factorii prognostici ai răspunsului și supraviețuirii după prima linie de chimioterapie în cancerele mamare local avansate. Volumul de rezumate la Congresul Național de Cancer - Poiana Brașov, 25-26 septembrie 1997:R16.

9.Volovăț C, Ghiorghiu S, Miron L, Carasevici E, Zugun-Eloae F. Factorii prognostici în limfoamele maligne non-hodgkiniene: o tentativă de aplicare a unui index prognostic. Volumul de rezumate la Congresul Național de Cancer - Poiana Brașov, 25-26 septembrie 1997:R17.

10.Miron L, Volovăț C, Toma C. Influența vârstei în tratamentul și supraviețuirea pacienților vârstnici cu forme local avansate de cancer mamare. Volumul de rezumate la Congresul Național de Cancer - Poiana Brasov, 25-26 septembrie 1997:R19.

11.C.Volovat, M.R.Galesanu, E.Tarcoveanu, L.Miron , Rezultatele adjuvantei cu 5Fluorouracil modulat cu acid folinic in cancerul colorectal – studiu retrospectiv in perioada 1994-1998 – Conferinta Nationala de Oncologie – iunie 1998 , Bucuresti

12.G.Crumpei, C. Volovat, Rolul suportului psihologic in cresterea calitatii vietii la pacientele cu cancer de san tratate multimodal – studiu pe 30 de cazuri –Conferinta Nationala de Oncologie – iunie 1998 , Bucuresti

13.C.Volovat , E.Tarcoveanu ,M.R.Galesanu , Felicia Crumpei, Studiu prospectiv cu privire la aportul chimioterapiei sistemice cu Gemcitabin in cancerul de pancreas avansat -

C.Volovat , E.Tarcoveanu ,M.R.Galesanu , Felicia Crumpei – Conferinta Nationala de Oncologie – iunie 1998 , Bucuresti 14.C.Volovat ,M.R.Galesanu, Studiul calitatii vietii la pacientii cu limfoame non-Hodgkin chimiotratati– Conferinta Nationala de Oncologie – iunie 1998 , Bucuresti

15.C.Volovat ,M.R.GalesanuAlternative la hormonorezistenta in cancerul de prostata avansat – studiu prospectiv , Conferinta Nationala de Oncologie – iunie 1998 , Bucuresti

16.C.Cojocaru, C. Volovat, T. Mihaescu, Caracteristicile cancerului pulmonar intr-un centru oncologic din Iasi, Romania - Conferința de Pneumologie - Cardiologie cu participare internațională , Iași, 29 Septembrie - 2 Octombrie 2004

04 SEP 23 

17.C. Volovat, B. Rotundu, Informatizarea cabinetelor judetene de oncologie ONCOBASE aplicatie practica –Lucrările Conferinței Naționale cu tema "Managementul informației și informatizarea sistemului de sănătate" - Iași, 29 septembrie - 2 octombrie 2004

18.C.Volovat, "An antibody belonging to a new class of bispecific antibodies" –Simpozionul "Catumaxomab in tratamentul ascitei maligne", Iasi – 15 dec 2005

19.C. Volovăț, C.C. Volovăț , B. Rotundu, Daniela Apostol, Parteneriatul public-privat în oncologie-oncbase-soft informațional în oncologia medicală -- A 2 a conferinta a CNAS „Managementul Informației și Informatizarea Sistemului de Sănătate”, 23-26 nov 2005

20.C. Volovăț, C.C. Volovăț , Daniela Apostol, Oncologia medicală în sistem privat - A 2 a conferinta a CNAS „Managementul Informației și Informatizarea Sistemului de Sănătate”, 23-26 nov 2005

21.Dunarea G. Ionescu, L. Miron, Rodica Chiriac, Cristina Tacu, C. Volovat, Dana Clement, Diana Petroiu, Dorin Hopulele, Dina Badarau, M. Marinca, Ostin C. Mungiu: Centrul de studiu si terapie a durerii – cinci ani de activitate-, Algeziologie și farmacologie : , Zilele Medicamentului –Ediția a XV-a, Editura Gr.T.Popa, Iași, 2006, p.17-21 (E)

c. Lucrări publicate în abstract (volume de rezumate la conferințe internaționale)

1.Miron L, Ciornea L, Volovăț C. The evaluation of response of Interferon alpha in advanced malignant melanoma. J BUON 1998;3(suppl.A):33(O89).

2.C. Volovat, G. Crumpei, The role of psychological support in the increase of life quality for breast cancer patients with multimodal treatment” –may 19-23, 1999 – International Meeting of Non-Governmental Organisations Against Cancer, Atlanta, GA

3.Miron L, Ciornea L, Volovăț C. IFN alpha - Therapy in advanced malignant melanoma. Program and abstracts of 11th Medditeranean Congress of chemotherapy, Tel Aviv, Israel, 18-21 octombrie 1998:18.

4.Florian Lordick , Yoon-Koo Kang , Pamela Salman , Sang Cheul Oh , Gyorgy Bodoky, Galina Petrova Kurteva , Constantin D. Volovat , Vladimir Moiseyenko , Akira Sawaki , Joon Oh Park , Vera A. Gorbunova , Heiko Goette , Helena Melezinkova ,Christopher Stroh , Markus Moehler, Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study. DOI: 10.1200/jco.2013.31.15_suppl.4021 Journal of Clinical Oncology 31, no. 15_suppl (May 2013) 4021-4021.

5.Constantin D. Volovat , Oleg Gladkov , Igor Bondarenko , Steven Barash , Anton Buchner , Noa Avisar , Peter Bias, Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy. DOI: 10.1200/jco.2012.30.15_suppl.9125 Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 9125-9125.

6.AliceT. Shaw, Doru Ghizdavescu, Minish Jain, Constantin Volovat, Deepa Subramaniam, Dale Shuster, Xiaoping Jin, Dipen Dutta, Seema Paiand Reinhard von Roemeling, Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as

04 SEP 23 

first-line therapy for metastatic non-small cell lung cancer (NSCLC), Proceedings: AACR 103rd Annual Meeting 2012-- Mar 31-Apr 4, 2012; DOI: 10.1158/1538-7445.AM20124606
Published April 2012

7.Oleg Gladkov , Constantin D. Volovat , Steven Barash , Anton Buchner , Noa Avisar, Peter Bias , Udo W. Mueller, Efficacy and safety of balugrastim in chemotherapy- induced neutropenia: Integrated analysis of two randomized phase III studies. DOI: 10.1200/jco.2013.31.15_suppl.e17572 Journal of Clinical Oncology 31, no. 15_suppl - published online before print.

8.Ioana Armasu^{1,2} , Iulia Crumpei^{1,2} , Constantin Volovat³ , Mariana Tofan³ , Valentin Zaharia² , Adrian Aancutei² , Ioana Vasiliu¹ , Ionela Lacramioara Serban¹ & Carmen Vulpoi^{1,2} Obesity, gonadotropic axis and breast cancer - is ghrelin the connexion? Endocrine Abstracts (2017) 49 EP809 | DOI: 10.1530/endoabs.49.EP809

9.Adina Manolachie¹ , Felicia Crumpei² , Constantin Volovat³ , Ioana Bodescu¹ , Jeanina Idriceanu¹ , Ioana Vasiliu¹ , Alina Fadur¹ , Cristina Preda¹ & Carmen Vulpoi¹ Pancreatic neuroendocrine tumour with a silent long evolution: case report Endocrine Abstracts (2014) 35 P592 | DOI: 10.1530/endoabs.35.P592

10.Iulia Crumpei¹ , Alina Fadur¹ , Adina Manolachie¹ , George Zmau¹ , Mihaela Anton² , Constantin Volovat³ , Maria Christina Ungureanu¹ & Carmen Vulpoi¹ Concomitance of pancreatic and neuroendocrine breast tumour - simple coincidence or not? Endocrine Abstracts (2015) 37 EP1343 | DOI: 10.1530/endoabs.37.EP1343

d. Articole publicate în extenso în reviste naționale indexate CNCSIS B/B+

1.Cancerul veziculei biliare - E. Târcoveanu, D. Niculescu, C. Lupașcu, Niculina Florea,D. Ferariu, D. Negru, Felicia Crumpei,C. Volovăț, N. Vlad, R. Moldovanu - Jurnalul de Chirurgie, Iasi, 2005, Vol. 1, Nr. 2 [ISSN 1584 – 9341]

2.Scripcariu V, Dajbog E, Lefter L, Danciu M, Ferariu D, Pricop A, Grigoraș M, Negru D, Volovăț C, Miron L, Drug V, Dragomir C. Features of pathological assessment in rectal cancer. Rev Med Chir Soc Med Nat Iasi 2006;110(3):590-597.

3.Volovăț C, Volovăț SR, Dogaru C, Vulpoi C. [Assessment of the quality of life of women with breast cancer in adjuvant treatment with tamoxifen or aromatase inhibitors--a randomized trial]. Rev Med Chir Soc Med Nat Iasi. 2011 Jan-Mar;115(1):53-7. Romanian. PubMed PMID: 21688560.

4.Armasu I, Volovăț C, Drug VL, Crumpei I, Vasiliu I, Tofan M, Preda C, Serban IL, Vulpoi C. IMPLICATIONS OF GHRELIN AXIS IN BREAST CANCER--REVIEW. Rev Med Chir Soc Med Nat Iasi. 2015 Apr-Jun;119(2):302-9. Review. PubMed PMID: 26204629.

04 SEP 23 